Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5475 for pulmonary hypertension associated with chronic obstructive pulmonary disease
2022-501201-13-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised trial in Pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD-PH) comparing MK-5475 with Placebo for MK-5475 (2 arms). Primary endpoint: Mean change from baseline in 6-minute walk distance at Week 24. Planned start Mar 2023; status: authorised.
02
Drugs
frespaciguat
03
Conditions
Pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD-PH)
Beyond the preview
Go deeper on 2022-501201-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501201-13-00.